Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

← catalyst calendar

NCT05052996 · results posted

Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
142actual
Sites
44
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2021-10-05actualWhen the study began enrolling
Primary completion2023-12-19actualThe date the last participant is measured for the primary outcome — the readout window
Study completionMar 2028estimatedThe whole study's end, after follow-up
First posted2021-09-22actualWhen this record first appeared on the registry
Results posted2025-01-14actualWhen the sponsor posted results to the registry
Record updated2026-02-04actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • HIV-1 Infection

Interventions

  • Drug: ISL
  • Drug: LEN — also filed as GS-6207
  • Drug: B/F/TAF — also filed as Biktarvy®
  • Drug: ISL/LEN FDC

Primary outcome

what the primary-completion date above is the date OF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm
measured Week 24

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol: Protocol Amendment 6posted 2025-12-02 · 2.7 MB · Prot_002.pdf
Study Protocol: Protocol Amendment 5posted 2024-11-19 · 3.8 MB · Prot_003.pdf
Statistical Analysis Planposted 2024-07-31 · 1.6 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed